From: Is new drug prescribing in primary care specialist induced?
Salmeterol/fluticasone | Ā | Ā | Ā |
---|---|---|---|
Ā | New drug N (%) | Reference drug N (%) | Relative Rate (95% CI) |
āāāMedical specialist | 103 (60.2%) | 302 (16.9%) | 3.56 (3.03ā4.17) |
āāāGP | 68 (39.8%) | 1,481 (83.1%) | Ref. |
Rofecoxib | Ā | Ā | Ā |
āāāMedical specialist | 137 (23.0%) | 1,445 (13.0%) | 1.77 (1.51ā2.06) |
āāāGP | 459 (77.0%) | 9,656 (87.0%) | Ref. |
Esomeprazole | Ā | Ā | Ā |
āāāMedical specialist | 53 (34.9%) | 424 (19.6%) | 1.78 (1.41ā2.25) |
āāāGP | 99 (65.1%) | 1,741 (80.4%) | Ref. |
Tiotropium | Ā | Ā | Ā |
āāāMedical specialist | 293 (52.7%) | 123 (14.5%) | 3.64 (3.03ā4.36) |
āāāGP | 263 (47.3%) | 726 (85.5%) | Ref. |
Rosuvastatin | Ā | Ā | Ā |
āāāMedical specialist | 89 (42.0%) | 355 (39.5%) | 1.06 (0.89ā1.27) |
āāāGP | 123 (58.0%) | 544 (60.5%) | Ref. |
Overall | Ā | Ā | Ā |
āāāMedical specialist | 675 (40.0%) | 2,649 (15.8%) | 2.53 (2.37ā2.71) |
āāāGP | 1,012 (60.0%) | 14,148 (84.2%) | Ref. |